Pharmacology Flashcards
Aspirin: MOA
Nonselective COX inhibitor
In platelets, aspirin irreversibly acetylates COX-1, inhibiting COX-1 –> prevents TxA2 synthesis and associated platelet aggregation
Aspirin: differential effect in platelets vs endothelial cells
Platelets express COX-1 –> TxA2 synthesis (PROMOTES platelet aggregation)
- Endothelial cells express COX-1 and COX-2 –> prostacyclin synthesis (INHIBITS platelet aggregation)
However, effect of aspirin in platelets lasts longer because platelets do not have a nucleus and cannot regenerate COX-1, thus tipping balance in favor of inhibited platelet aggregation
Aspirin: dose dependent effect
Low doses: anti-thrombotic
Higher doses: anti-inflammatory (3-5g/day)
Aspirin: adverse effects
- Bleeding
- GI upset and ulcers (COX-1 involved in production of stomach mucus)
- Renal toxicity (prostaglandins involved in vasodilation of afferent arteriole and regulation of GFR)
Aspirin in kids after viral illness: consequence
Reye Syndrome: hepatic injury and encephalopathy in kids –> AVOID!!
Aspirin: indications
Arterial thrombosis: MI, stroke, peripheral artery disease, angina, atrial fibrillation, during and post PCI (percutaneous coronary intervention, aka stent)
Clopidogrel: MOA
Irreversible ADP receptor antagonist
Prodrug requiring CYP activation
Clopidogrel: indications
Pre-PCI: bolus given
After-PCI: clopidogrel + aspirin for one year
ADP receptor antagonists: name 3
“GREL’s”
1) Clopidogrel (irreversible, prodrug)
2) Prasugrel (irreversible, prodrug, faster kinetics)
3) Ticagrelor (reversible, NOT a prodrug)
GpIIb/IIIa inhibitors: name 3
Abciximab
Tirofiban
Eptifibitide
GpIIb/IIIa inhibitors: indications
During PCI (only IV), and after for 12-24 hours
Anticoagulants: indications
Both venous and arterial: PE, DVT, MI, acute coronary syndromes
Heparin: MOA
Catalyzes antithrombin-3 (AT3) inactivation of thrombin and factor Xa
Low molecular weight (LMW) heparin (enoxaparin): MOA
Catalyzes antithrombin-3 (AT3) inactivation of factor Xa (like fondaparinux)
Fondaparinux: MOA
Catalyzes antithrombin-3 (AT3) inactivation of factor Xa (like enoxaparin)
LMWH and fondaparinux: monitoring
None needed. Can use anti-Xa testing
Thrombin: rate limiting step, which comes AFTER Factor Xa